We investigated the role of donor cytomegalovirus (CMV) serostatus on reactivation of CMV infection in CMV-infected transplant recipients. Reactivation of CMV infection occurred more frequently in patients receiving a CMVpositive graft but was less severe than in patients receiving a CMV-negative graft. These data suggest roles for both virus as well as CMV-specific immunity present in the graft.
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT) [1] . Studies have shown that the use of a CMV-negative graft in a CMV-positive patient is linked to the occurrence of late reactivation of CMV infection [2] in patients with preceeding early reactivation of CMV infection and have provided some support for an association with the development of CMV-related disease [3, 4] . In accordance with this, it was recently reported that CMV-positive SCT recipients receiving a CMVnegative transplant are twice as likely to require antiviral therapy [5, 6] . However, no data exist on the actual association of donor CMV serostatus and the onset and severity of reactivation of CMV infection. Therefore, we investigated whether CMV serostatus of the donor influences the onset of viral reactivation, as well as the magnitude of the viral reactivation, which was defined by maximum viral load reached early after SCT in CMV-positive recipients.
METHODS
Consecutive CMV-positive patients were prospectively observed for 6 months after allogeneic SCT. Patients received transplants during the period from October 2005 through January 2009 at the Department of Hematology of the University Medical Center Utrecht (Utrecht, the Netherlands). Written informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Patient characteristics are summarized in Table 1 . Patients received an allogeneic SCT from either an unrelated (n 5 61) or a related donor (n 5 47). A nonmyeloablative conditioning regime was used in most patients (n 5 96). Anti-thymocyte globulin was added to the conditioning regime for in vivo T cell depletion in patients receiving grafts from unrelated donors or graft from human leukocyte antigen-mismatched donor (n 5 65).
CMV serostatus of patients and donors was determined as part of the standard diagnostic routine: 50 patients received a graft from a CMV-positive donor, and 56 received one from a CMV-negative donor; status was unknown for 2 transplant recipients. CMV monitoring was based on a real-time TaqMan CMV-DNA polymerase chain reaction (PCR) assay in EDTAtreated plasma [7] . This assay was performed weekly in all patients as part of the diagnostic routine until 6 months after transplantation and enabled identification of early cases of reactivation. Patients were treated preemptively with valganciclovir (900 mg twice daily) if the CMV -DNA load was .500 copies/mL. Valaciclovir was given prophylactically (500 mg twice daily) to all patients. On the basis of this clinical threshold for antiviral therapy, we studied the magnitude of the viral reactivation (or 500 copies/mL) as a read out for reactivation severity.
All transplantation risk factors for reactivation of CMV infection were assessed using a v 2 test and a Cox regression test for multivariate analysis. The incidence of reactivation of CMV infection was determined using a Kaplan-Meier graph and log rank test. Differences between viral loads were assessed using the Mann-Whitney U test. A probability level of 5% (P , .05) was considered statistically significant. All statistical analysis were performed using SPSS software, version 12.1 (SPSS), and GraphPad Prism software, version 5.0 (Graphpad Software).
RESULTS AND DISCUSSION
One hundred eight CMV-positive allogeneic stem cell recipients were prospectively monitored for viral reactivation during the first 6 months after SCT. Viral reactivation was defined as CMV-DNA load exceeding the detection limit of 50 copies/mL. Reactivations were categorized into low and high reactivation on the basis of the peak viral load exceeding a clinically relevant threshold of 500 copies/mL plasma, which is based on the threshold for preemptive therapy. Viral reactivation occurred in Comparison between the reactivation and no reactivation group was performed using the Mann-Whitney U t test for age, Multivariate analysis was performed using Cox regression. AA, aplastic anemia; aGVHD, acute graft versus host disease; ALL, acute lymphatic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; CI, confidence interval; CLL, chronic lymphatic leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; HES, hypereosinofil syndrome; MA, myeloablative; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NMA, non myeloablative; XLP, X-linked lymphoproliferative disease.
BRIEF REPORT
Transplant-related factors that could influence the onset of viral reactivation were assessed (Table 1) . Age (P 5 .035), conditioning regimen (P 5 .016), and CMV status of the donor (P 5 0,000) were all predictors of viral reactivation. All transplantation-related factors with P , .2 were analyzed in a multivariate Cox regression test. Transplantation factors that were significantly associated with the onset of viral reactivation were conditioning regimen (hazard ratio [HR], 0.220; 95% CI, 0.060-0.798; P 5 .019), anti-thymocyte globulin administration (HR, 0.426; 95% CI, 0.231-0.786; P 5 .006), acute graft-versus-host disease (HR, 0.516; 95% CI, 0.300-0.886; P 5 .017), and the CMV serostatus of the donor (HR, 0.387; 95% CI, 0.219-0.683; P 5 .001). The association of conditioning regimen with reactivation of CMV infection can be explained by the limited number of patients receiving a myeloablative transplantation in our study (n 5 12), 3 of whom experienced reactivation of CMV infection.
Next, we analyzed the relationship between donor CMV serostatus and the occurrence of reactivation of CMV infection early after SCT. We found that, reactivation of CMV infection occurred much more frequently in patients receiving a CMV-positive graft than in patients receiving a CMV-negative graft ( Figure 1A ). Within 6 months after SCT, reactivation of CMV infection occurred in 79.0% of patients who received a graft from a CMV-positive donor, compared with 39.3% of patients who received a CMV-negative graft (P , .001). There was no difference in onset of viral reactivation between the 2 groups. Patients receiving a CMVnegative graft developed reactivation of CMV infection at a median of 17 days after SCT (range, 0-136 days), compared with 22 days for patients receiving a CMV-positive graft (range, 3-104 days; P 5 .45). To investigate whether donor CMV status influences the severity of the viral reactivation, we subsequently analyzed the peak CMV DNA load reached by each patient undergoing viral reactivation <6 months after 001) . B, Higher CMV load levels after SCT with a CMV-negative graft. The maximum CMV viral load levels (in copies per mililiter) measured in plasma during 6 months after SCT is plotted for each patient who experienced reactivation of CMV infection (n 5 62) based on CMV serostatus. The median viral load for CMV-negative graft recipients was 1439 copies/mL, compared with 355 copies/mL in CMV-positive graft recipients (P 5 .003). C, Prolonged CMV DNA positivity in recipients of CMV-negative grafts. The median duration (in days; y-axis) of CMV DNA positivity is plotted for each patient who experienced reactivation of CMV infection on the basis of CMV serostatus. Patients who died within the 6-month time frame (n 5 17) were omitted from the analysis. Median duration of positivity was 117 days for patients receiving a CMV-negative graft, compared with 43.5 days for patients receiving a CMV-positive graft (P 5 .002). SCT (n 5 62). The percentage of patients with high reactivations (n 5 33; CMV load, .500 copies/mL) was significantly higher in the group receiving CMV-negative grafts (72.7% of reactivations) than in the group receiving CMVpositive grafts (42.1% of reactivations; P 5 .032). We plotted the maximum viral load obtained <6 months after SCT for patients receiving CMV-negative or CMV-positive transplants ( Figure 1B) . SCT recipients receiving a CMV-negative graft reached significantly higher peak viral loads (median, 1439 copies/mL; range, 66-22,811 copies/mL) than did patients receiving a CMV-positive graft (median, 354.5 copies/mL; range, 50-11,257 copies/mL; (P 5 .003) ( Figure 1B) . We subsequently investigated the duration of the viral reactivation. For each patient, we calculated the number of days of reactivation of CMV infection during the first 6 months after SCT by combining the duration of all episodes in which the CMV DNA PCR result was positive. We excluded patients who had died within this timeframe (n 5 17). Patients receiving a CMV-negative graft had more and longer episodes of reactivation of CMV infection (median, 117 days of positive CMV DNA PCR results; range, 21-139 days) that did patients receiving a CMV-positive graft (median, 43.5 days of positive CMV DNA PCR results; range, 12-110 days; P 5 .002) (Figure 1c) .
Thus, although reactivation of CMV infection occurred more often in CMV-positive patients after transplantation with a CMV-positive graft, the viral reactivation was less severe and was short-lasting, compared with SCT recipients of a CMVnegative graft. The higher viral loads and prolonged time frame of CMV DNAemia is in concordance with a recent publication by Zhou et al [5] , in which recurrent and prolonged use of antiviral therapy was shown for CMV-positive recipients of a CMV-negative graft.
We postulate that the more frequent detection of CMV in recipients of a CMV-positive graft may be caused by (re)-activation of the CMV strain of the donor. This has previously been shown to occur for Epstein-Barr virus (EBV) infections. Active EBV infections after allogeneic SCT were shown to frequently result from reinfection with an exogenous EBV strain instead of being a true reactivation of the endogenous strain [8] . This hypothesis should be further explored in a future study that would be specifically designed to tackle this question by, for example, obtaining saliva samples of the donor before transplantation and comparing CMV strains in these specimens with the initially present CMV strain in saliva samples from the donor and the reactivating CMV strain (in either blood or saliva). However, retrospective identification of the CMV strain in the donor is very difficult-if not impossible-because of undetectable CMV levels in the blood.
Furthermore, lower viral loads occurring in recipients of a CMV-positive graft could be due to the transfer of CMVspecific immunity from the graft. Presence of CMV-specific T cells in the graft could result in a faster CMV-specific T cell reconstitution in the recipient, resulting in better containment of viral reactivation. This transferred immunity has been previously shown for herpes simplex virus reactivation after SCT [9] . Ganepola et al [10] suggest that a delay in CMV-specific T cell immunity in seropositive recipients of a CMV-negative donor causes frequent CMV infections and disease. Gratama et al [11] have also suggested that CMV-specific T cells in the CMV-positive graft could protect against progressive CMV infection, because they have shown that the number of CMV-specific CD8 1 T cells in the graft inversely correlated with the number of recurrent CMV infections requiring preemptive antiviral treatment. More recently, it was shown that the reconstitution of CMVspecific T cells after SCT was determined by the characteristics of the CMV-specific T cells in the donor. The same CMV antigens were targeted in both the donor and the recipient. In addition, less differentiated CMV-specific T cell responses in the donor persisted in the recipient, whereas terminally differentiated cells in the donor decreased after SCT in the recipient [12] . Furthermore, Zhou et al [5] demonstrated rapid reconstitution of multifunctional CD8
1
T cells in CMV-positive recipients after receipt of an SCT from a CMV-positive donor, suggesting that this early expansion is derived from the CMV-specific T cells of the donor. Unfortunately, the clinical group studied is heterogeneous, with respect to the use of related versus unrelated donor grafts and diagnosis, previously shown to be associated with a higher risk for reactivation of CMV infection [2] . Therefore, a less heterogeneous patient population (eg, a population of only matched siblings or of patients with more similar diseases) would improve the analysis. In summary, the higher incidence of viral reactivation in CMV-positive recipients of CMV-positive stem cell grafts may be caused by reactivation of the donor CMV strain; because this reactivation may be subsequently controlled by CMV-specific T cells from the graft, this would lead to only mild viral reactivations. On the other hand, we observed that more severe viral reactivations occur with CMV-negative grafts. Because of the lack of CMV-specific T cells in the graft, control of reactivation of CMV infection likely depends on reconstitution and activation of naive T cells, which take more time to develop. These data suggest roles for both virus as well as CMV-specific immunity present in the graft.
